It is proposed to conduct an interrelated series of experiments to elucidate the biochemical mechanism of the antagonism of the nutritional utilization of selenium (Se) by mercaptans. The project developed out of our interest in metabolic and nutritional responses to Se with likely involvement of Se-dependent factors other than the only well characterized one (Se-dependent glutathione peroxidase, SeGSHpx). In preliminary work, in which mercaptan compounds, recently shown to be potent inhibitors of SeGSHpx in vitro, were tested in vivo, several were found to reduce tissue activities activities of SeGSHpx and to potentiate clinical signs of Se-deficiency. Because the in vivo effect on SeGSHpx is not explainable by direct inhibition of the enzyme, it is of interest to learn the mechanism involved and whether it also involves more general aspects of Se metabolic function. Therefore, this project was designed to address these questions with regard to the immediate implications to the health of populations with limited Se intakes. If the antagonism of Se by mercaptans is not specific for SeGSHpx, as hypothesized, then the activities of these compounds may have important implications to the treatment of selenosis. The experiments in this plan use established animal models and biochemical methods. Two mercaptans. D-(-)-penicillamine and beta-mercaptopyruvate, will be used as model mercaptans. Because the former is also a chelator of Cu, experiments will be conducted to partition effects on Cu and/or Zn from those on Se utilization. The results can be expected to yield information relevant to both the mode of action of mercaptans and the metabolic function of Se.
| Lu, J X; Combs Jr, G F (1992) Penicillamine: pharmacokinetics and differential effects on zinc and copper status in chicks. J Nutr 122:355-62 |
